These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion. Peña JR; Saidman SL; Girouard TC; Meister E; Dzik WH; Makar RS Am J Hematol; 2014 Sep; 89(9):E133-7. PubMed ID: 24816643 [TBL] [Abstract][Full Text] [Related]
6. INTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without) clinical refractoriness in published studies. Benjamin RJ; Corash L; Norris PJ Transfusion; 2020 Apr; 60(4):881-882. PubMed ID: 32246477 [No Abstract] [Full Text] [Related]
7. [Platelet transfusion refractoriness and effective management of platelet alloimmunization]. Amemiya Y Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306 [TBL] [Abstract][Full Text] [Related]
8. [Transfusion of platelet concentrates]. Rieux C; Lee K; Lavaud A; Bierling P Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645 [TBL] [Abstract][Full Text] [Related]
9. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion. Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A Front Immunol; 2018; 9():1251. PubMed ID: 29951051 [TBL] [Abstract][Full Text] [Related]
10. A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions. Revelli N; Villa MA; Olivero B; Bresciani S; Flores M; Marini M; Pizzi MN; Prati D; Rebulla P Vox Sang; 2019 Jan; 114(1):73-78. PubMed ID: 30523641 [TBL] [Abstract][Full Text] [Related]
11. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM]. Dettori I; Ladaique P Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204 [TBL] [Abstract][Full Text] [Related]
12. Dominant immune response to HLA-B57/B58 molecules after platelet transfusion. Coombs J; Ben Hassen L; Leclerc M; Tamagne M; Pannetier L; Khelfa M; Delorme A; Bocquet T; Maury S; Pirenne F; Ansart-Pirenne H; Vingert B Transfusion; 2020 Dec; 60(12):2807-2814. PubMed ID: 33037638 [TBL] [Abstract][Full Text] [Related]
13. Post-transfusion purpura caused by anti-HPA-3a antibodies that are only detectable using whole platelets in the platelet immunofluorescence test. Barba P; Pallarés P; Nogués N; Canals C; Gracia M; Vinyets I; Muñiz-Diaz E Transfus Med; 2010 Jun; 20(3):200-2. PubMed ID: 19919615 [No Abstract] [Full Text] [Related]
14. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A; Picard C Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [TBL] [Abstract][Full Text] [Related]
16. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [TBL] [Abstract][Full Text] [Related]